BeiGene's sNDA for tislelizumab accepted in China

|About: BeiGene, Ltd. (BGNE)|By:, SA News Editor

China National Medical Products Administration (NMPA) has accepted BeiGene's (NASDAQ:BGNE), supplemental new drug application (sNDA) for tislelizumab, an investigational anti-PD-1 antibody, for the treatment of patients with previously treated locally advanced or metastatic urothelial carcinoma (UC).

Additionally, BeiGene is conducting a Phase 3 clinical trial in first-line patients with non-squamous NSCLC; squamous NSCLC; nasopharyngeal cancer and a Phase 2 trial in patients with MSI-H or dMMR solid tumors. These studies are enrolling patients in China.

Subscribe for full text news in your inbox